Marea Therapeutics Launched Phase 2 Acromegaly Trial
The study evaluates a monoclonal antibody designed to reduce IGF-1 levels in patients with excess growth hormone.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you believe new pharmaceutical therapies are successfully reducing the burden of managing chronic health conditions?
Marea Therapeutics, a subsidiary of Lisata Therapeutics, has dosed the first patient in a Phase 2 clinical trial for MAR002. The research-stage study evaluates the efficacy of an allosteric monoclonal antibody in treating acromegaly, a chronic disorder caused by excess growth hormone.
Why it matters
Acromegaly can reduce life expectancy by a decade if left untreated, driving the clinical need for therapies that provide disease control with fewer injections than current daily standards. Marea is testing whether MAR002 can achieve clinical endpoints with infrequent dosing.
The study measures IGF-1 reduction after 10 weeks of treatment across three dose arms against a placebo. MAR002 is an allosteric monoclonal antibody—a lab-created protein that binds to specific cell receptors—designed to block growth hormone signaling.
The players
Marea Therapeutics
A South San Francisco-based subsidiary of Lisata Therapeutics focused on developing monoclonal antibody treatments for metabolic and endocrine disorders.
Lisata Therapeutics
A Liberty Corner, New Jersey-based biotechnology company that maintains Marea Therapeutics as a subsidiary while developing a pipeline of therapeutic candidates.
The details
MAR002 acts as an allosteric monoclonal antibody, which binds to a site on the growth hormone receptor distinct from the primary binding site to inhibit signaling. By blocking this pathway, the drug aims to regulate the excess growth hormone exposure characteristic of acromegaly. The trial design uses a 900 mg loading dose followed by maintenance doses to investigate if the drug can safely manage hormone levels with a frequency as low as once every two weeks.
Timeline
June 2026: Phase 1 trial results were presented.
October 5, 2026: The first patient was dosed in the Phase 2 clinical trial.
The Tech Race
This study advances Marea Therapeutics along the clinical development path following the Phase 1 results presented in June 2026. The company is now attempting to demonstrate that MAR002 offers a best-in-class profile by reducing injection frequency compared to current standards for the roughly 30,000 patients in the U.S.
This clinical trial is currently in the research stage and not yet available to the public. Eligible participants may gain access to the drug through the 72-person study or a subsequent open-label extension trial.
The takeaway
Marea Therapeutics is pushing to optimize treatment for the estimated 30,000 acromegaly patients in the U.S. who face significant life-expectancy risks. Watch for future disclosures regarding the 10-week primary endpoint data to see if the drug meets its goal of bi-weekly dosing.
Further reading
For more developments in clinical research, visit the Biotech section.
Live Poll
Do you believe new pharmaceutical therapies are successfully reducing the burden of managing chronic health conditions?
